NEW YORK, NY -- (Marketwired) -- 08/24/15 --
Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D., President and CEO, will be presenting on behalf of the company at the 2015 Sidoti Emerging Growth Conference in New York City, NY on Wednesday, September 2, 2015 at 11:20amET in Winter Garden Room at The Marriot Marquis in Time Square. Investors and interested parties may listen to the live webcast of this presentation or replay the webcast of this presentation by visiting www.webcaster4.com/Webcast/Page/1223/10211
About Sidoti & Company
The Sidoti 2015 Emerging Growth Conference is a unique forum where emerging growth company management teams with a market cap of $1 billion or less connect with small and micro-cap institutional investors, research analysts, investment bankers, private equity professionals and select media with the goal of expanding institutional awareness amongst key stakeholders in the investment community. The 2015 Emerging Growth Conference will be held on September 2, 2015 at the Marriott Marquis in Times Square New York. The event is one of the leading small and micro-cap investment conferences of the year featuring presentations by more than 50 public companies, with past attendance exceeding 475 investors.
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2015. We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for the use of proceeds of the financing, our plans to begin enrolling patients in clinical trials for the treatment of Sanfilippo syndrome, development and internationalization of other clinical programs, management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contact:
Director of Communications
Abeona Therapeutics, Inc.
Source: Abeona Therapeutics